SCHEMBL2566987

SCHEMBL2566987

CCCCC(CC)COc1ccc(-c2ccc(-c3ccc(-c4ccc(OCC(CC)CCCC)cc4)s3)s2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 7/20 0.41
▸ CYP2D6 P10635 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ APP P05067 3/20 0.41
▸ ALDH1A1 P00352 5/20 0.40
▸ MAPT P10636 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ CA2 P00918 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CYP19A1 P11511 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ LMNA P02545 3/20 0.37
▸ TSHR P16473 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15786690 0.92 CYP3A4 (0.41) CYP3A4CYP2D6CYP1A2APPALDH1A1
SCHEMBL21387865 0.89 RAB9A (0.40) CYP3A4CYP2D6CYP1A2APPALDH1A1
SCHEMBL2572427 0.88 APP (0.48) CYP3A4CYP2D6CYP1A2APPALDH1A1
SCHEMBL20357876 0.86 CYP3A4 (0.47) CYP3A4CYP2D6CYP1A2ALDH1A1CA2
SCHEMBL16265238 0.86 CYP3A4 (0.36) CYP3A4CYP2D6CYP1A2APPALDH1A1
SCHEMBL17551040 0.86 CYP3A4 (0.36) CYP3A4CYP2D6CYP1A2APPALDH1A1
SCHEMBL1357035 0.84 ALDH1A1 (0.50) CYP3A4ALDH1A1CA2TDP1L3MBTL1
SCHEMBL1356320 0.84 ALDH1A1 (0.50) CYP3A4ALDH1A1CA2TDP1L3MBTL1
SCHEMBL2572347 0.84 CYP2D6 (0.42) CYP3A4CYP2D6CYP1A2APPALDH1A1
SCHEMBL16265316 0.84 CYP3A4 (0.35) CYP3A4CYP2D6CYP1A2APPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943239-B1 PHENYLENE-THIOPHENE OLIGOMERS AS ORGANIC SEMICONDUCTORS BASF SE (DE) 2011-11-09 — — EP claimed
US-7569415-B2 Liquid phase fabrication of active devices including organic semiconductors ALCATEL-LUCENT USA INC. (US) 2009-08-04 — — US claimed
US-7488834-B2 Organic semiconductors ALCATEL-LUCENT USA INC. (US) 2009-02-10 — — US claimed
EP-1943239-A1 PHENYLENE-THIOPHENE OLIGOMERS AS ORGANIC SEMICONDUCTORS BASF SE (DE) 2008-07-16 — — EP claimed
EP-1943688-A1 LIQUID PHASE FABRICATION OF ACTIVE DEVICES INCLUDING ORGANIC SEMICONDUCTORS BASF SE (DE) 2008-07-16 — — EP claimed
EP-1943690-A1 ORGANIC COMPOSITIONS BASF SE (DE) 2008-07-16 — — EP claimed
WO-2007039575-A1 LIQUID PHASE FABRICATION OF ACTIVE DEVICES INCLUDING ORGANIC SEMICONDUCTORS BASF SE (DE) 2007-04-12 — — WO claimed
WO-2007039547-A1 ORGANIC COMPOSITIONS BASF SE (DE) 2007-04-12 — — WO claimed
WO-2007039574-A1 PHENYLENE-THIOPHENE OLIGOMERS AS ORGANIC SEMICONDUCTORS BASF SE (DE) 2007-04-12 — — WO claimed
US-20070078267-A1 Organic semiconductors ALCATEL-LUCENT USA INC. 2007-04-05 — — US claimed
US-20070077681-A1 Liquid phase fabrication of active devices including organic semiconductors ALCATEL-LUCENT USA INC. 2007-04-05 — — US claimed
US-20070075630-A1 Organic compositions BASF AKTIENGESELLSCHAFT (DE) 2007-04-05 — — US claimed
EP-1943239-B1 PHENYLENE-THIOPHENE OLIGOMERS AS ORGANIC SEMICONDUCTORS BASF SE (DE) 2011-11-09 — — EP disclosed
US-7569415-B2 Liquid phase fabrication of active devices including organic semiconductors ALCATEL-LUCENT USA INC. (US) 2009-08-04 — — US disclosed
US-7569415-B2 Liquid phase fabrication of active devices including organic semiconductors ALCATEL-LUCENT USA INC. (US) 2009-08-04 — — US disclosed
US-7488834-B2 Organic semiconductors ALCATEL-LUCENT USA INC. (US) 2009-02-10 — — US disclosed
US-20070078267-A1 Organic semiconductors ALCATEL-LUCENT USA INC. 2007-04-05 — — US disclosed
US-20070078267-A1 Organic semiconductors ALCATEL-LUCENT USA INC. 2007-04-05 — — US disclosed
US-20070077681-A1 Liquid phase fabrication of active devices including organic semiconductors ALCATEL-LUCENT USA INC. 2007-04-05 — — US disclosed
US-20070075630-A1 Organic compositions BASF AKTIENGESELLSCHAFT (DE) 2007-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078267-A1 Organic semiconductors ORC3, C1S, C5 CYP3A4 1717/4885CYP2D6 3097/4885CYP1A2 1375/4885
US-20070075630-A1 Organic compositions BPNT1, RFT1, FERMT2 CYP3A4 926/4885CYP2D6 1780/4885CYP1A2 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback